Review
Published on 16 Nov 2023
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1239118
- 2,395 views
- 1 citation
Type at least 3 characters
1,703 articles
Articles
Original Research
Published on 14 Nov 2023
The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1235158
- 917 views
- 1 citation
Original Research
Published on 14 Nov 2023
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1283951
- 1,516 views
- 1 citation
Retraction
Published on 10 Nov 2023
Retraction: The oncolytic virus in cancer diagnosis and treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1320477
- 1,532 views
Case Report
Published on 09 Nov 2023
Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1260706
- 985 views
- 1 citation
Mini Review
Published on 08 Nov 2023
Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1244775
- 2,079 views
Review
Published on 07 Nov 2023
Advances in the relationship between ferroptosis and epithelial–mesenchymal transition in cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1257985
- 1,692 views
Review
Published on 07 Nov 2023
Cuproptosis: emerging biomarkers and potential therapeutics in cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1288504
- 3,809 views
- 6 citations
Case Report
Published on 07 Nov 2023
Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1245547
- 1,452 views
- 1 citation
Original Research
Published on 06 Nov 2023
Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1110807
- 1,470 views
Original Research
Published on 02 Nov 2023
Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1287797
- 1,737 views
- 1 citation
Original Research
Published on 02 Nov 2023
Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1250558
- 2,166 views
- 1 citation
Original Research
Published on 30 Oct 2023
Fanconi anemia pathway regulation by FANCI in prostate cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1260826
- 1,761 views
- 2 citations
Review
Published on 27 Oct 2023
Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1278282
- 2,273 views
Review
Published on 26 Oct 2023
The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1261090
- 2,307 views
- 1 citation
Original Research
Published on 25 Oct 2023
Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1240868
- 1,312 views
- 1 citation